BCL2 and lymphoma: Moreover, this efficacy extended to cell lines derived from a mouse model developing lymphoma as a result of oncogenic B-cell specific expression of Myd88L252P and BCL2 [32], which mimic the constitutive NF-κB activation observed in ABC-type DLBCL (Fig. 2D).